Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 69 for:    ORLISTAT

Orlistat/Phentermine Versus Placebo/Phentermine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03675191
Recruitment Status : Not yet recruiting
First Posted : September 18, 2018
Last Update Posted : September 18, 2018
Sponsor:
Information provided by (Responsible Party):
Ji-Won Lee, Gangnam Severance Hospital

Brief Summary:

The prevalence of obesity is increasing worldwide and obesity is an important risk factor for cardiovascular disease. In addition, back pain has been increasing steadily due to sitting life, lack of exercise, wrong posture, and obesity. Recent studies found that obesity and back pain are common diseases and are closely related to each other. People with back pain have lower physical activity, which in turn leads to an weight gain and a deterioration in physical performance. Among the drugs used for obesity, orlistat has been approved for long-term use, and phentermine, the most commonly used drug, has been approved for short-term use. However, phentermine can increase blood pressure and pulse rate. Meanwhile, several studies have shown that orlistat, a pancreatic lipase inhibitor, lowers blood pressure and pulse rate and diminish LDL-cholesterol. Lowering LDL-C could lead to improved vascular endothelial function.

The investigators aimed to investigate the effect of orlistat and phentermine combination therapy on weight loss and improvement of vascular function compared to phentermine monotherapy in obese patients (BMI 27 kg/m2) with metabolic risk and back pain.


Condition or disease Intervention/treatment Phase
Obesity Overweight Drug: Orlistat 120Mg Cap Drug: Phentermine Pill Not Applicable

Detailed Description:

The investigators aimed to investigate the effect of orlistat and phentermine combination therapy on weight loss and improvement of vascular function compared to phentermine monotherapy in obese patients (BMI 27 kg/m2) with metabolic risk and back pain.

Randomized placebo-controlled clinical trials (12 weeks), Patients: Obese patients (BMI 27 kg/m2) with metabolic risk and back pain

The patients were divided into two groups: orlistat (120mg, three times a day), phentermine (37.5 mg, once a day) combined Group (N = 57), placebo (placebo, three times a day) and phentermine (37.5 mg, once a day) Group (N=57).

Randomly assigned to each group at 1: 1, and allocation codes are generated using SAS (Ver. 9.2). The investigators provide orlistat and phentermine or placebo and phentermine. The investigators check physical measurement, blood test, questionnaire, blood pressure and pulse, body composition, FMD, heart rate variability test, in the first visit. The investigators check for changes in body weight, compliance, and side effects after 4 weeks and 8 weeks, respectively. After 12 weeks, the investigators re-check physical measurement, blood test, questionnaire, blood pressure and pulse, body composition, FMD, heart rate variability test.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Randomized placebo-controlled clinical trials (12 weeks)

  • orlistat (120mg, three times a day, within 1hour after meal) + phentermin (37.5mg, once a day, within 1hour after meal)
  • placebo (120mg, three times a day, within 1hour after meal) + phentermin (37.5mg, once a day, within 1hour after meal) The patients were divided into two groups: orlistat (120mg, three times a day), phentermine (37.5 mg, once a day) combined Group (N = 57), placebo (placebo, three times a day) and phentermine (37.5 mg, once a day) Group (N=57)
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:

The placebo pill is given to participants who are randomly assigned to the control group.

Double-blinded

Primary Purpose: Treatment
Official Title: The Effects of Orlistat/Phentermine Versus Placebo/Phentermine Treatment on Weight Loss and Vascular Function of Overweight Patients With Back Pain
Estimated Study Start Date : September 12, 2018
Estimated Primary Completion Date : September 12, 2020
Estimated Study Completion Date : September 12, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: orlistat
Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
Drug: Orlistat 120Mg Cap
Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
Other Name: Lipidown Cap

Drug: Phentermine Pill
Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
Other Name: Phentermine Pill 37.5mg

Placebo Comparator: placebo
placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
Drug: Phentermine Pill
Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
Other Name: Phentermine Pill 37.5mg




Primary Outcome Measures :
  1. Body mass index changes [ Time Frame: 12weeks ]
    Body mass index in kg/m2.

  2. Vascular function changes [ Time Frame: 12weeks ]
    Vascular function will be assessed using the flow mediated dilatation (%).


Secondary Outcome Measures :
  1. Back pain [ Time Frame: 12weeks ]
    Assessments using a Visual Analog Score for pain Visual Analog Scale (total score 10, minimum;0, no pain, maximum; 10, severe pain)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • After a screening test, the characteristics of the trial were explained and then the patient voluntarily agreed to participate in the study and signed a consent form with IRB approval.
  • Adults over 20 years of age at the time of obtaining consent
  • A back pain score of 3 and a metabolic risk of a BMI greater than 27 kg / m2.
  • Metabolic risk includes the following, according to the American Endocrinology Society (AACE) guidelines. (Diabetic stage, metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease, nonalcoholic fatty liver, polycystic ovary syndrome, obstructive sleep apnea, osteoarthritis, gastroesophageal
  • In the case of a pregnant woman, pregnancy test is negative
  • Patients who can understand and speak Korean
  • Patients whose physicians approved to participate in the study
  • Patients who are able to complete the study without participating in other intervention studies (drug, diet, exercise intervention studies) during the study period.
  • Patients who agreed to contraception during the study

Exclusion Criteria:

  1. Persons who are contraindicated for Phentermine Sympathomized excitable amines sensitive patients or patients with specific qualities Progressive arteriosclerosis patients Patients with symptomatic cardiovascular disease When there is pulmonary hypertension or heart valve disease A patient with hyperthyroidism A patient with glaucoma Patients who are extremely anxious or excited mentally person who had history of drug abuse Patients taking other central nervous system stimulants or those 14 days after the administration of MAO inhibitors (MAOIs)
  2. Persons who are contraindicated for Orlistat Patient with chronic malabsorption syndrome or patient who stops secretion of juice Patients with hypersensitivity to this or this component
  3. Uncontrolled hypertenstion (SBP>180mmHg or DBP >120mmHg)
  4. Under taking anti-diabetics or fasting blood glucose >=200mg/dl
  5. If your weight has decreased by more than 5 kg in the last 3 months
  6. (AST or ALT> 3 times the normal value) or kidney disease (serum creatinine> 2.0 mg / dL)
  7. Patients taking other clinical trial drugs
  8. Patients taking other appetite suppressants within the last 30 days
  9. Acute infectious diseases such as pneumonia, acute enteritis, and acute urinary tract infections
  10. If you are participating in other clinical trials
  11. Those who are deemed unsuitable for participating in this study by the researcher

Layout table for additonal information
Responsible Party: Ji-Won Lee, Associate professor, Gangnam Severance Hospital
ClinicalTrials.gov Identifier: NCT03675191     History of Changes
Other Study ID Numbers: 3-2018-0210
First Posted: September 18, 2018    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Orlistat
Overweight
Body Weight
Signs and Symptoms
Phentermine
Central Nervous System Stimulants
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents